ReviewAdvances in experimental medicine and biology2026
Glycan Structures of Human Immunoglobulins and Their Roles.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulins (Igs) are antibodies that specifically recognize foreign bodies and induce immune responses. Among the five classes of Igs in humans, IgG, IgA, IgM, IgD, and IgE, human IgG is one of the most intensively studied glycoproteins because of its central role in the immune system as a major serum antibody and its effectiveness in clinical applications. The three-dimensional structures of human IgG with glycosylation suggest that subtle differences in glycan structures affect the protein structure of IgG, leading to significant differences in immune responses. To generate more effective antibody medicines, glycoengineering techniques have recently made it possible to manipulate antibodies with only specified N-glycan structures on the Fc region of IgG. In addition to the human IgG, the glycan structures and site occupancies at glycosylation sites on other Ig classes have also been investigated in detail by glycomics/glycoproteomics analysis using mass spectrometry. Human IgA and IgM are also expected to be used as therapeutic antibodies due to their unique properties and functions in the immune system. Site-specific glycan structures on IgD and IgE from a single donor can be analyzed using highly sensitive glycoproteomics, regardless of their relatively small amount in human serum. Although N-glycans of each Ig class often have similar structures, the degree of their contributions to the interaction with Fc receptors varies among the classes.
Indexed as
Identifiers
41917392What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.